These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9064108)

  • 1. Pamidronate infusions for the treatment of Paget's disease of bone.
    Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
    Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
    Arboleya L; Sánchez J; Iglesias G; Arranz JL
    Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    Chakravarty K; Merry P; Scott DG
    J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
    Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
    Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
    Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F
    Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paget's disease of bone: experience from a centre in southern India.
    Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
    J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
    Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
    J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
    Tucci JR; Bontha S
    Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
    Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
    Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.